These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 14722051)

  • 1. The prognostic significance of indium-111-capromab penetide.
    Sodee DB; Faulhaber PF; Nelson AD; Bakale G
    J Clin Oncol; 2004 Jan; 22(2):379-80; author reply 380-1. PubMed ID: 14722051
    [No Abstract]   [Full Text] [Related]  

  • 2. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy.
    Thomas CT; Bradshaw PT; Pollock BH; Montie JE; Taylor JM; Thames HD; McLaughlin PW; DeBiose DA; Hussey DH; Wahl RL
    J Clin Oncol; 2003 May; 21(9):1715-21. PubMed ID: 12721246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indium-111-capromab pendetide scans: an important test relevant to clinical decision making.
    Sartor O; McLeod D
    Urology; 2001 Mar; 57(3):399-401. PubMed ID: 11248605
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
    Raj GV; Partin AW; Polascik TJ
    Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indium-111 capromab pendetide (ProstaScint) images before and after salvage radiation therapy.
    Welsh JS; Yanez MH; Chin BB; Howard SP
    Clin Nucl Med; 1999 Dec; 24(12):983. PubMed ID: 10595485
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer.
    Nagda SN; Mohideen N; Lo SS; Khan U; Dillehay G; Wagner R; Campbell S; Flanigan R
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):834-40. PubMed ID: 17293236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization of (111)In-Capromab pendetide SPECT-CT for detecting seminal vesicle invasion with recurrent prostate cancer after primary in situ therapy.
    Kimura M; Tsivian M; Mouraviev V; Mayes JM; Price MM; Bannister MC; Madden JF; Wong TZ; Polascik TJ
    Int J Urol; 2009 Dec; 16(12):971-5. PubMed ID: 19843189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary imaging results using In-111 labeled CYT-356 (Prostascint) in the detection of recurrent prostate cancer.
    Sodee DB; Conant R; Chalfant M; Miron S; Klein E; Bahnson R; Spirnak JP; Carlin B; Bellon EM; Rogers B
    Clin Nucl Med; 1996 Oct; 21(10):759-67. PubMed ID: 8896922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indium-111 capromab pendetide in the management of recurrent prostate cancer.
    Manyak MJ
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):175-81. PubMed ID: 18279057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology.
    Wong TZ; Turkington TG; Polascik TJ; Coleman RE
    AJR Am J Roentgenol; 2005 Feb; 184(2):676-80. PubMed ID: 15671397
    [No Abstract]   [Full Text] [Related]  

  • 11. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer.
    Rosenthal SA; Haseman MK; Polascik TJ
    Tech Urol; 2001 Mar; 7(1):27-37. PubMed ID: 11272670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy.
    Wilkinson S; Chodak G
    J Urol; 2004 Jul; 172(1):133-6. PubMed ID: 15201753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of radioimmunoscintigraphy with indium-111-labeled CYT-356 (ProstaScint) scan for evaluation of patients for salvage brachytherapy.
    Fang DX; Stock RG; Stone NN; Krynyckyi BR; Kim CK; Machac J
    Tech Urol; 2000 Jun; 6(2):146-50. PubMed ID: 10798816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PROSTASCINT scan for staging prostate cancer.
    Lange PH
    Urology; 2001 Mar; 57(3):402-6. PubMed ID: 11248606
    [No Abstract]   [Full Text] [Related]  

  • 15. In reply to Zilli and Miralbell.
    D'Angelillo RM; Ramella S; Trodella L
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):682. PubMed ID: 25680611
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial comment. Capromab pendetide scanning has a potential role in optimizing patient selection for salvage cryosurgical ablation of the prostate.
    Shore ND
    Urology; 2010 Nov; 76(5):1167-8; author reply 1168. PubMed ID: 21056261
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer.
    Koontz BF; Mouraviev V; Johnson JL; Mayes J; Chen SH; Wong TZ; Anscher MS; Sun L; Moul J; Polascik TJ
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):358-61. PubMed ID: 18164863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose salvage radiation therapy for prostate cancer after relapse: in regard to D'Angelillo et al.
    Zilli T; Miralbell R
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):681-2. PubMed ID: 25680610
    [No Abstract]   [Full Text] [Related]  

  • 19. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide.
    Hinkle GH; Burgers JK; Neal CE; Texter JH; Kahn D; Williams RD; Maguire R; Rogers B; Olsen JO; Badalament RA
    Cancer; 1998 Aug; 83(4):739-47. PubMed ID: 9708939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indium-111 capromab pendetide (ProstaScint) uptake in neurofibromatosis.
    Khan A; Caride VJ
    Urology; 2000 Jul; 56(1):154. PubMed ID: 10869655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.